Table 2. Characteristics of Major Responders (CR/nPR).

Characteristic	CR + nPR (N=11)	NR (N=19)
Median age (range), y	59 (47-78)	59 (42-74)
Male, no. (%)	10 (91)	15 (79)
Median no. of prior regimens (range)	1 (1-4)	3 (1-8)
Fludarabine-refractory disease, no. (%)	3 (30)	14 (78)
Prior therapy with rituximab, no. (%)	11 (100)	19 (100)
Prior therapy with alemtuzumab, no. (%)	1 (9)	3 (16)
Rai stage III and IV, no. (%)	3 (27)	13 (68)
Median β-2-microglobulin, mg/dL (range)	2.5 (1.7-5.4)	5.3 (2.4-9.5)

CR indicates complete response; nPR, nodular partial response; NR, no response.